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ABSTRACT 
Numerous plants are listed in the Ayurvedic pharmacopoeia, and several different plant parts are being used 
in Ayurvedic formulations. The bioactive ingredients of many of these medicinal have been identified. A key 
step in Ayurvedic drug development is the identification and validation of biological targets of these 
bioactive ingredients. Most of the experimental techniques involving genomic, proteomic and metabolomic 
approaches for target identification are laborious and expensive. Computational approaches allow an 
efficient alternative approach for in silico target prediction of bioactive compounds. Here, we have used 
computational methods to predict the target proteins of major bioactive compounds present in seven 
medicinal plants (Bacopa monnieri, Centella asiatica, Clitoria ternatea, Acorus calamus, Glycyrrhiza glabra, 
Celastrus paniculatus, Nardostachys jatamansi) known for their nootropic properties. These plants/plant 
parts are being used in various traditional Ayurveda formulations intended for cognitive enhancement and 
memory boosting. Even though these plants are widely used in the treatment of cognitive deficits, their 
scientific evaluation is lacking. Till date, very few studies have attempted to elucidate the targets or to 
explain the mode of action of bioactive ingredients in nootropic medicinal plants. We have chosen three 
databases for target prediction- ChEMBL, Swiss Target Prediction, and Binding DB. Based on available 
literature, we also examined if any of the predicted target proteins have brain-related functions. Pertinent to 
the nootropic properties of the medicinal plants, our study revealed several potential target proteins such as 
CYP19A1, MAPT, PTGS1, ACHE, SLC6A2, SLC6A3, MAOA and MAOB implicated in neurodevelopment, 
neuroprotection, learning and memory.  
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INTRODUCTION
 Ayurveda, which means “science/knowledge of 
life”, is a traditional system of alternative medicine in India 
making use of medicinal plants. Ayurveda is well 
renowned for its efficacy in the treatment of a variety of 
diseases and conditions including asthma, arthritis, 
rheumatism, skin diseases, spondylosis, gastric problems, 
neurological disorders and paralysis.  
 Numerous species of plants are listed in the 
Ayurvedic pharmacopoeia, and different types of plant 
parts are used in Ayurvedic formulations. The 
pharmacologically active (bioactive) ingredients of many 
medicinal plants used in Ayurveda have been identified. A 
key step in this process is target identification and 
validation. [1] There is a range of genomic, proteomic and 
metabolomic techniques that predicts or explains the 
mode of action of bioactive compounds. [2,3] However, such 
experimental techniques have been laborious and 
expensive. Novel computational approaches such as in 
silico target prediction is a well-established alternative 
approach for predicting the targets of bioactive 
compounds. [4-6]  
 Here, we have used computational methods to 
predict the target proteins of major bioactive compounds 
present in 7 medicinal plants that are known for their 
nootropic properties. These plants/plant parts are being 
used in various traditional Ayurveda formulations such as 
Saraswatharishta, Brahma rasayana, Brahmi ghrita and 
Manasamitra vadakam, intended for cognitive 
enhancement and memory boosting. Cognitive deficits in 
neurodevelopmental and neurodegenerative disorders 
demand the use of nootropics to boost cognitive abilities. 
Ayurvedic drugs prepared from these plants have been 
found to possess anti-inflammatory properties, have a 
calming effect on the central nervous system, and act as 
nootropics enhancing memory, learning and other 
cognitive functions. [7] Even though these plants and their 
formulations are widely used in the treatment of cognitive 
deficits, their scientific evaluation is lacking. Till date, very 
few studies have attempted to elucidate the targets or to 
explain the mode of action of bioactive ingredients in 
nootropic medicinal plants.  
Materials and Methods 
A list of medicinal plants selected for this study is given in 
Table 1. 
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Table 1: Medicinal plants with nootropic activity 
Botanical name Local name Useful part Pharmacological activity References 
Bacopa monnieri Brahmi Whole plant Cognitive enhancement [39] 
Centella asiatica  Kudangal Whole plant Memory enhancement [40] 
Clitoria ternatea Sankupushpam Root Brain tonic; enhancement of 
memory and intelligence 
[41] 
Acorus calamus Vayambu Root Memory enhancement [42] 
Glycyrrhiza glabra Earattimaduram Root Memory improvement [43] 
Celastrus paniculatus  Jyothishmathi Seed Cognitive enhancement; 
memory improvement 
[44] 
Nardostachys jatamansi Jatamanchi Rhizome Improvement of memory and 
learning; neuroprotective 
[45,46] 
  
 Three databases were chosen for target prediction, viz. ChEMBL (https://www.ebi.ac.uk/chembl/), Swiss Target 
Prediction (http://www.swisstargetprediction.ch/) and Binding DB (https://www.bindingdb.org/bind/index.jsp). Target 
prediction in these databases is based on the chemical structure of the bioactive ingredient which was provided as 
simplified molecular-input line-entry system (SMILES), a line notation representing molecules. Based on available 
literature, we also examined if any of the predicted target proteins have brain-related functions or has been implicated in 
neurological disorders.  
Results and Discussion 
The predicted target proteins of various bioactive ingredients of the 7 medicinal plants are listed in Table 2.  
Table 2. Bioactive ingredients of medicinal plants and their predicted target proteins 
Botanical 
name 
Bioactive 
compound 
Chemical 
nature 
Molecular 
formula 
Target prediction 
ChEMBL Swiss Target BindingDB 
Bacopa 
monnieri 
Bacoside A,B Triterpenoid 
Saponin 
C41H68O13  FLT1 
FLT4 
KDR 
ATP1A1 
HSD11B1 
HSD11B2 
KLF5 
LYST 
NR3C1 
Centella asiatica  Asiaticoside Triterpene 
glycoside 
 
C48H78O19 
 
PYGM  F2 
STAT1 
STAT2 
STAT3 
STAT4 
Clitoria 
ternatea 
Taraxerol Triterpenoid C30H50O NOS2 ACHE 
AR 
BCHE 
CYP19A1 
CYP51A1 
HMGCR 
LDLR 
LRP8 
PTPN1 
PTPN2 
SLC6A2 
SLC6A3 
SLC6A4 
TDP1 
VLDLR 
AR 
CYP19A1 
CYP51A1 
HMGCR 
PTPN1 
 
Taraxerone Triterpenoid C30H48O NOS2 CYP17A1 
CYP19A1 
ESR1 
ESR2 
FAAH 
MAPT 
MBNL1 
MBNL2 
MBNL3 
CYP19A1 
ESR1 
MAPT 
PTGS1 
PTGS2 
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NR3C1 
NR3C2 
PTGS1 
PTGS2 
SRD5A1 
SRD5A2 
Acorus calamus α-asarone 
β-asarone 
Ether C12H16O3 
 
CYP3A4 
CYP2D6 
HMGCR 
CYP19A1 
ESR1 
ESR2 
GFER 
MAPT 
NQO1 
NQO2 
MAOA 
MAOB 
MC1R 
PTGS1 
PTGS2 
TUBB1 
TUBB8 
ABCB1 
ABCG2 
AHR 
ALOX5AP 
APP 
CYP1A1 
CYP1A2 
CYP19A1 
CYP1B1 
ESR1 
MAPT 
NQO2 
PTGS1 
PTGS2 
TUBB 
TUBB1 
XIAP 
Glycyrrhiza 
glabra 
Glycyrrhetic 
acid 
Triterpenoid C30H46O4 AKR1B1 
AKR1B10 
CYP1A2 
CYP2D6 
CYP2C9 
CYP2C19 
CYP3A4 
GMNN 
HSD11B1 
HSD11B2 
HSD17B1 
HSD17B2 
LMNA 
MAPT 
POLK 
PPARG 
PRKCD 
PRKCH 
PTPN1 
PTPN2 
PTPN6 
PTPN7 
PTPN11 
RHO 
SLCO1B1 
SLCO1B3 
AKR1A1 
AKR1B1 
AKR1B10 
AKR1B15 
AKR1E2 
AR 
HSD11B1 
HSD11B1L 
HSD11B2 
PRKCE 
PRKCH 
PTPN6 
PTPN11 
AKR1B10 
AR 
CYP1A2 
HSD11B1 
HSD11B2 
PRKCH 
PTPN1 
PTPN2 
PTPN11 
SLCO1B1 
SLCO1B3 
Glycyrrhizin Saponin 
glycoside 
C42H62O16 HSD11B1 
HSD11B2 
NR3C1 
PTPN1 
HSD11B1 
HSD11B1L 
HSD11B2 
HSD11B1 
HSD11B2 
NR3C1 
PTPN1 
Chalcone Aromatic ketone C15H12O ALOX5 
AR 
MAOA 
MAOB 
ALOX5 
CRYZ 
MAOA 
MAOB 
MAPT 
MBNL1 
MBNL2 
MBNL3 
ALOX5 
AR 
MAOB 
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TLR9 
Coumarin Benzopyrone C9H6O2 CA1 
CA2 
CA3 
CA4 
CA5A 
CA5B 
CA12 
CA13 
CA14 
CYP2A6 
MAOA 
CA1 
CA2 
CA3 
CA4 
CA5A 
CA5B 
C6 
C7 
C9 
CA12 
CA13 
CA14 
MBNL1 
MBNL2 
MBNL3 
CA1 
CA9 
CA12 
CA13 
CA14 
CYP2A6 
DAO 
MAOA 
PGR 
Celastrus 
paniculatus  
Paniculatine Alkaloid C17H27NO2 
 
 ACHE 
AR 
BCHE 
DPP4 
EBP 
FAP 
HSD11B1 
HSD11B1L 
HSD17B3 
HSD17B12 
NR3C1 
NR3C2 
SIGMAR1 
SLC6A2 
SLC6A3 
HSD17B3 
ACHE 
BCHE 
Nardostachys 
jatamansi 
Valeranone Sesquiterpene 
 
C15H26O 
 
 AR 
CA1 
CA13 
CA2 
CA3 
CA5A 
CA5B 
CA7 
CES1 
CES2 
CES3 
CES5A 
CYP19A1 
MAPT 
ALOX5 
AR 
CA2 
CES1 
CES2 
CYP19A1 
GPBAR1 
HPD 
For each bioactive compound, common targets predicted by 2 or more databases are shown in bold 
 
 For the bioactive ingredients (Glycyrrhetic acid, 
Glycyrrhizin, Chalcone and Coumarin) of Glycyrrhiza 
glabra, some protein targets were predicted in common by 
all the 3 prediction databases. A consensus was observed 
among the target proteins predicted by at least 2 
databases for Clitoria ternatea, Acorus calamus, Celastrus 
paniculatus and Nardostachys jadamansi. Different targets 
were predicted by the 3 databases for Bacopa monnieri 
and Centella asiatica. Several of the predicted target 
proteins have brain-related functions pertinent to their 
nootropic effects as discussed below. 
 Plants are a rich source of novel 
pharmacologically active compounds. To date, >70,000 
plant species have been screened for their medicinal use. 
[8] Drug discovery from plants, driven by bioactivity-
dependent fractionation, has led to the discovery of many 
important drugs. Several of these bioactive ingredients, 
through a better understanding of their target interactions, 
mode of action and clinical implications, have found new 
medical applications. In silico analysis of these bioactive 
compounds are very helpful to establish their mode of 
action. Our study revealed several potential target proteins 
involved in neurodevelopmental or neuroprotection 
processes. 
 CYP19A1, also known as aromatase which 
catalyzes the formation of aromatic C18 estrogens from 
C19 androgens, was predicted to be a target of taraxerol 
and taraxerone of C. ternatea, α asarone and β asarone of 
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A. calamus, and valeranone of N. jadamansi. Estrogen has 
neurotrophic and neuroprotective effects in the brain. [9] 
Several genetic and functional lines of evidence support a 
role of CYP19A1 in reading, speech and language.[10] A 
chromosomal translocation in a dyslexic individual was 
found to disrupt the promoter region of CYP19A1.[10] 
Interestingly, CYP19A1 gene is located in 15q21 locus, 
which is also known to harbor DYX1C1 gene implicated in 
developmental dyslexia.[11] Moreover, expression of 
CYP19A1 was found to be altered in Alzheimer’s disease 
(AD), [12] and several reports suggest a genetic association 
of CYP19A1 gene polymorphism with AD. [13,14] Thus, it is 
an important finding that the bioactive ingredients of the 
medicinal plants used to enhance cognitive abilities have 
CYP19A1 as one of their target proteins.  
 Microtubule associated protein tau (MAPT) was 
predicted as the target of taraxerone of C. ternatea, α 
asarone and β asarone of A. calamus, glycyrrhetic acid and 
chalcone of G. glabra, and valeranone of N. jadamansi. 
Depending on the neuron type and stage of neuronal 
maturation, the MAPT transcripts are differentially 
expressed in the nervous system. [15] MAPT mutations have 
been associated with several neurodegenerative disorders 
such as Alzheimer's disease (AD), [16] Parkinson's disease, 
[17] Pick's disease, [18] frontotemporal dementia, [19] cortico-
basal degeneration [20] and progressive supranuclear palsy. 
[21] Besides, the risk of mild cognitive impairment[22] 
cognitive decline [23] and memory decline [24] was found to 
be influenced by genetic variations in MAPT.  
 PTGS1 (COX1) and PTGS2 (COX2) were predicted 
to be targets of taraxerone of C. ternatea, and α asarone 
and β asarone of A. calamus. Several lines of evidence 
indicate a role of PTGS1 and PTGS2 in the pathogenesis of 
AD. [25-27] Studies in mice have provided evidence that 
PTGS1 and PTGS2 have a potential role in learning and 
memory. [28-30] In fact, inhibition of PTGS1 and PTGS2 has 
been suggested as a possible therapeutic approach for AD 
[29] as well as for cognitive impairments. [31,32] 
 ACHE was predicted as the target of taraxerol (C. 
ternatea) and paniculatine (C. paniculatus). Known as a 
neuromodulator, there is accumulating evidence on the 
role of acetylcholine in learning and memory. [33,34] In a 
mouse model of autism, elevation of acetylcholine was 
found to relieve cognitive rigidity and social deficiency. [35] 
SLC6A2 and SLC6A3 were predicted as targets of taraxerol 
(C. ternatea) and paniculatine (C. paniculatus). SLC6A2 and 
SLC6A3 genes have been reported to be associated with 
attention deficit hyperactivity disorder in several studies 
(reviewed by Farone and Mick). [36] 
 MAOA and MAOB were predicted as targets of α-
asarone and β-asarone (A. calamus) and chalcone and 
coumarin (G. glabra). Data from humans and animal 
models suggest that inhibition of MAOA and MAOB lead to 
cognitive enhancement, which could be used in the 
treatment of cognitive disorders. [37,38] 
 Our study to identify the target proteins of 
bioactive compounds present in Ayurvedic medicinal 
herbs with nootropic properties has revealed several 
potential target proteins implicated in neurodevelopment 
and neuroprotection.  
 
CONCLUSION 
 The target proteins identified through in silico 
target fishing have been implicated in neurodevelopmental 
or neuroprotection processes. 
 Modern approaches to Ayurveda warrant further 
in-depth drug development efforts, including development 
of single molecule drugs. This would require vast 
knowledge on the isolation of a substance in pure form 
using various separation techniques, its chemical 
properties and spectral characteristics. Advances in 
instrumentation and computational methods have now 
opened up new possibilities for the use of this knowledge 
in identifying multiple targets, aiding drug development 
research. 
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